VTVT Logo

vTv Therapeutics Inc. (VTVT) 

NASDAQ$20.99
Market Cap
$54.83M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
310 of 924
Rank in Industry
177 of 527

VTVT Insider Trading Activity

VTVT Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$83,8122100
Sells
$000

Related Transactions

SEKHRI PAUL JPres, CEO and Exec Chairperson2$83,8120$0$83,812

About vTv Therapeutics Inc.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule â€¦

Insider Activity of vTv Therapeutics Inc.

Over the last 12 months, insiders at vTv Therapeutics Inc. have bought $83,812 and sold $0 worth of vTv Therapeutics Inc. stock.

On average, over the past 5 years, insiders at vTv Therapeutics Inc. have bought $1.45M and sold $100,050 worth of stock each year.

Highest buying activity among insiders over the last 12 months: SEKHRI PAUL J (Pres, CEO and Exec Chairperson) — $83,812.

The last purchase of 1,844 shares for transaction amount of $31,269 was made by SEKHRI PAUL J (Pres, CEO and Exec Chairperson) on 2024‑11‑18.

List of Insider Buy and Sell Transactions, vTv Therapeutics Inc.

2024-11-18PurchaseSEKHRI PAUL JPres, CEO and Exec Chairperson
1,844
0.058%
$16.96$31,269-8.58%
2024-11-15PurchaseSEKHRI PAUL JPres, CEO and Exec Chairperson
3,156
0.1377%
$16.65$52,543-11.15%
2022-11-29PurchaseFRY JOHN Adirector
40,461
0.0852%
$0.83$33,773-12.01%
2022-11-28PurchaseFRY JOHN Adirector
20,539
0.0431%
$0.83$16,969-11.38%
2021-12-20SalePERELMAN RONALD Odirector
87,000
0.154%
$1.15$100,050-26.54%
2021-02-26PurchaseNelson Rich S.director
60,000
0.1142%
$2.86$171,600-31.58%
2021-02-26PurchaseKOZLOV HERSHdirector
10,000
0.0182%
$2.74$27,400-31.58%
2020-12-17PurchasePERELMAN RONALD Odirector
625,000
0.9225%
$1.60$1M-2.36%
2020-12-10PurchasePERELMAN RONALD Odirector
625,000
0.893%
$1.60$1M-4.79%
2020-11-24PurchasePERELMAN RONALD Odirector
625,000
1.0514%
$1.60$1M+13.44%
2020-05-15PurchaseKOZLOV HERSHdirector
10,000
0.022%
$3.00$30,000-22.48%
2020-05-12PurchasePERELMAN RONALD Odirector
625,000
0.8555%
$1.60$1M-8.98%
2020-02-25PurchasePERELMAN RONALD Odirector
1.25M
1.438%
$1.60$2M-33.44%
2020-01-28PurchasePERELMAN RONALD Odirector
1.25M
2.1109%
$1.60$2M-2.29%
2020-01-07PurchasePERELMAN RONALD Odirector
1.25M
2.5998%
$1.60$2M+20.34%
2019-12-18PurchasePERELMAN RONALD Odirector
1.37M
4.3437%
$1.46$2M+40.13%
2019-11-26PurchasePERELMAN RONALD Odirector
1.37M
4.4914%
$1.46$2M+42.86%
2019-11-12PurchasePERELMAN RONALD Odirector
1.37M
4.3437%
$1.46$2M+38.16%
2019-10-24PurchasePERELMAN RONALD Odirector
1.37M
4.2053%
$1.46$2M+33.76%
2019-09-26PurchasePERELMAN RONALD Odirector
1.37M
4.3232%
$1.46$2M+45.83%
Total: 90
*Gray background shows transactions not older than one year

Insider Historical Profitability

13.96%
SEKHRI PAUL JPres, CEO and Exec Chairperson
5000
0.1914%
$104,950.0020
PERELMAN RONALD Odirector
36519212
1397.993%
$766.54M611+17.2%
SAVAS PAUL Gdirector
91781
3.5135%
$1.93M160+66.67%
FRY JOHN Adirector
61000
2.3351%
$1.28M20<0.0001%
Nelson Rich S.director
50000
1.9141%
$1.05M10<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$81,638,324
48
7.58%
$59.66M
vTv Therapeutics Inc.
(VTVT)
$77,062,892
41
13.96%
$54.83M
$6,787,959
35
49.84%
$61.13M
$459,011,221
33
33.04%
$58.46M
$2,239,226
28
3.41%
$58.08M

VTVT Institutional Investors: Active Positions

Increased Positions6+33.33%10,192+1.88%
Decreased Positions3-16.67%467-0.09%
New Positions<1New1,803New
Sold Out Positions3Sold Out467Sold Out
Total Postitions21+16.67%552,049+1.79%

VTVT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Samsara Biocapital, Llc$3,071.006.89%206,78400%2024-12-31
Fmr Llc$2,646.005.94%178,20000%2024-12-31
Baker Bros. Advisors Lp$1,445.003.24%97,31400%2024-12-31
Vanguard Group Inc$617.001.39%41,55800%2024-12-31
Geode Capital Management, Llc$173.000.39%11,634+1,327+12.88%2024-12-31
Ubs Group Ag$112.000.25%7,512+6,646+767.44%2024-12-31
Blackrock, Inc.$71.000.16%4,773+23+0.48%2024-12-31
Jpmorgan Chase & Co$27.000.06%1,803+1,803New2024-12-31
Morgan Stanley$17.000.04%1,146+306+36.43%2024-12-31
Planning Capital Management Corp$9.000.02%62500%2024-09-30

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
2SellsBuysStrong BuyBuyHoldSellStrong Sell